ECP 2026: Operational Gains with AI in Breast Pathology

Multi-center study reports benefits to diagnostic confidence, costs, and efficiencies after AI implementation

1

The DeBORAH Study evaluated an AI algorithm's impact on diagnostic accuracy in breast core biopsy reporting across five NHS centers.
2

The AI demonstrated over 99% sensitivity and specificity for overall cancer diagnosis and over 96% for ductal carcinoma in situ.
3

Pathologists reported increased confidence and efficiency, with some centers showing up to a 72% reduction in immunohistochemistry orders.
4

Cost reductions per patient ranged from £1.80 to £17.70, with turnaround times decreasing by up to 17 hours.
5

User satisfaction surveys indicated that pathologists found the AI easy to use and would recommend it to colleagues.

1